Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04960514 · ClinicalTrials.gov registry record
Prospective Decision Impact Trial of KidneyIntelX
A clinical trial of Diabetic Kidney Disease and Chronic Kidney Disease Stage 2, sponsored by Renalytix AI.
- Active
- Registry status
- 2,000
- Enrollment target
- 1
- Study location
NCT04960514: Active study of Diabetic Kidney Disease and Chronic Kidney Disease Stage 2, sponsored by Renalytix AI.
NCT04960514 is a study of Diabetic Kidney Disease and Chronic Kidney Disease Stage 2 that is active but no longer recruiting, run by Renalytix AI. The registered enrollment target is 2,000 participants, below the 5,103-participant average among 23 other Diabetic Kidney Disease trials with a reported enrollment target (61% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04960514, a study of Diabetic Kidney Disease and Chronic Kidney Disease Stage 2, is active but no longer recruiting, sponsored by Renalytix AI.
- ACTIVE NOT RECRUITING
- Registry status
- 2,000 participants
- Enrollment target
- 1
- Study location
Study Summary
The current trial is designed to evaluate how the results of KidneyIntelX test / platform impacts on the clinical management of type 2 diabetes patients identified as increased risk for rapid kidney function decline within 5-years.
Primary Outcome
Proportion (target: 20% increase from prior measurements) of visits in which each participant achieves target blood pressure of \<140/90 mmHg (as per the NKF CKD management guidelines).
Conditions Studied
Interventions
- DIAGNOSTIC_TEST KidneyIntelX
Study Locations (1)
North Carolina
- Atrium Health Wake Forest Baptist - Family Medicine - Piedmont Plaza - Winston-Salem
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2,000 participants |
| Start Date | 2021-11-22 |
| Est. Completion | 2026-12-01 |
What the registry record for NCT04960514 still lists
NCT04960514 is an observational study that tracks outcomes without assigning an intervention. Its 2,000 participants enrollment target places it among the larger protocols in the corpus, below the 5,103-participant average among 23 other Diabetic Kidney Disease trials with a reported enrollment target (61% lower).
The record links to 4 conditions, with Diabetic Kidney Disease appearing as the primary indexed condition, and to 1 intervention - of which KidneyIntelX is the first listed.
NCT04960514 reports a single indexed study location in North Carolina.
Frequently Asked Questions
What is clinical trial NCT04960514 about?
NCT04960514 is a clinical study titled "Prospective Decision Impact Trial of KidneyIntelX". The current trial is designed to evaluate how the results of KidneyIntelX test / platform impacts on the clinical management of type 2 diabetes patients identified as increased risk for rapid kidney function decline within 5-years.
What is the current status of trial NCT04960514?
This trial is currently active not recruiting. The enrollment target is 2,000 participants. The study started on 2021-11-22. Estimated completion is 2026-12-01.
What conditions does trial NCT04960514 study?
This clinical trial studies the following conditions: Diabetic Kidney Disease, Chronic Kidney Disease Stage 2, Chronic Kidney Disease Stage 1, Chronic Kidney Disease, Stage 3 (Moderate).
What interventions are being tested in trial NCT04960514?
The interventions under investigation include: KidneyIntelX (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT04960514?
This trial is sponsored by Renalytix AI, which has 4 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04960514 being conducted?
This trial has 1 study location across North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Diabetic Kidney Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04960514's enrollment target sits among peer trials
2,000 4th of 23 higher than 19 of 23 other Diabetic Kidney Disease trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Diabetic Kidney Disease trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
MANATEE-T1D: Metformin ANd AutomaTEd Insulin Delivery System Effects on Renal Vascular Resistance, Insulin Sensitivity, and Cardiometabolic Function in Youth With Type 1 Diabetes
RECRUITING · Phase 1
-
Family Investigation of Nephropathy and Diabetes (F.I.N.D.)
RECRUITING
-
Formoterol in Diabetes
RECRUITING · Phase 2
-
Mechanism of SGLT2 Inhibition in the Kidney
RECRUITING · Phase 4
-
Dosimetry of Tc-99m-Tilmanocept
RECRUITING · Phase 1
-
A Long-Term Follow-Up Study of Participants Exposed to REACT
RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00001465 · 2,000 participants
Study of the Disease Process of Lymphangioleiomyomatosis
- NCT00001595 · 2,000 participants
An Investigation of Pituitary Tumors and Related Hypothalmic Disorders
- NCT00138931 · 2,000 participants
Genetics of Cardiovascular and Neuromuscular Disease
- NCT00288119 · 2,000 participants
Genetic Determinants of Barrett's Esophagus and Esophageal Adenocarcinoma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI